Project Grant R21AR079755
Award Date
9/15/23
Completion Date
8/31/26
Dollars Obligated
$537K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Gainesville, FL 32611, USA
Similar Awards
This $1,104,029 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program will support research at the University of Florida to investigate MRI/MRS markers of skeletal muscle disease progression and vascular function in non-ambulatory individuals with Duchenne muscular dystrophy (DMD). The research will be conducted over a 3-year period from November 1, 2024 to October 31, 2027. The funding will enable the University of...
The University of Florida received a $1,166,594 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, titled "EARLY CARDIAC BIOMARKERS OF INFLAMMATION AND REMODELING IN DMD", will fund research to investigate innovative approaches to early detection and treatment of cardiac complications associated with Duchenne muscular dystrophy (DMD). The 4-year project, commencing on September 1, 2025...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to develop enabling technologies for safe and effective gene editing in skeletal muscle. The $531,109 grant awarded to the University of Florida will fund research to address key challenges in applying gene editing to skeletal muscle diseases, including maximizing delivery and spread of editing...
This $953,125 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program will support research at the University of Florida to investigate MRI/MRS markers of skeletal muscle disease progression and vascular function in nonambulatory individuals with Duchenne muscular dystrophy. The research project will run from November 1, 2024 to October 31, 2027 and aims to advance understanding of neurodegenerative diseases...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $671,240 project grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to the University of Washington to develop improved gene therapy approaches for Duchenne muscular dystrophy (DMD). The project aims to refine technologies for expressing larger and more functional dystrophin and utrophin proteins using adeno-associated virus (AAV) vectors, as well as enhance dystrophin gene...
This federal Project Grant award, worth $1,727,423, was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under their Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The objective of this 5-year award, which began on August 7, 2024, is to investigate the role of the bone-regulating myokine FGF21 in Duchenne muscular dystrophy (DMD) and its effects on skeletal health. The research will focus on identifying the cellular...
This $306,872 Project Grant awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under CFDA 93.846 is supporting Vivreon Biosciences, LLC, a life sciences company in San Diego, California, to develop a novel small molecule therapeutic targeting the ORAI1 calcium channel for treating Duchenne muscular dystrophy (DMD) and other dystrophinopathies. The key objectives of this 2-year project are to assess the toxicity profile of the therapeutic candidate and...
This $1,601,933 federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research into developing C2 domain therapeutics for muscular dystrophy. The primary awardee, the University of Maryland, Baltimore, will lead efforts to optimize engineered constructs of the dysferlin C2A domain to rescue deficits in calcium signaling and membrane repair in...
The University of Florida (UF) received a $1,524,836 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to conduct research on understanding and targeting common mechanisms of myotonic dystrophy types 1 and 2 using novel repeat expansion mouse models. The grant, which began on September 1, 2023 and will continue through August 31, 2027, supports UF's cutting-edge biomedical research efforts to transform healthcare for Service...
Under a $1,525,000 Project Grant awarded by the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development), the University of Florida's Division of Sponsored Research will conduct research to "UNDERSTANDING AND TARGETING COMMON MECHANISMS OF MYOTONIC DYSTROPHY TYPES 1AND 2 USING NOVEL REPEAT EXPANSION MOUSE MODELS." This 4-year research project, commencing on Sep 1, 2023, will advance the understanding and treatment of myotonic dystrophy, a genetic disorder that...